TICKERNERD
Menu
BIVIBIVIHealthcare · Biotechnology

BIVI Stock Forecast: BioVie, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.93
+1.05% on the day

The 2 Wall Street analysts covering BioVie, Inc. hold a median 12-month price target of $5.26 — +172.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$16.3M
Ticker Nerd rank
26 / 100
Median analyst target
$5.26
Analysts covering
2
Revenue$0.0
Operating income−$5.7M
Net income−$5.6M
Free cash flow−$4.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.9%
1M
+52.0%
YTD
+66.4%
1Y
+2.7%
From 52W high
−15.4%
From 52W low
+100.2%
$0.96
$2.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIVI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
63
Volatility
46
Momentum
44
Quality
35
Issuance
32
Revisions
29
Growth
25
Value
18

Size (89): Smaller than most of the companies we track.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIVI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIVI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26BIVIHigh $5.51Median $5.26Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $5.00Median $5.26High $5.51

The green dot is the last close — the median target sits +172.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 July 2024ThinkEquityInitiatesBuy$3.00
30 Nov 2023OppenheimerMaintainsOutperform—
22 Aug 2023Cantor FitzgeraldReiteratesOverweight—
18 July 2023Cantor FitzgeraldReiteratesOverweight—
17 May 2023Cantor FitzgeraldReiteratesOverweight—
17 May 2023OppenheimerReiteratesOutperform—
14 Feb 2023OppenheimerReiteratesOutperform—
28 Sept 2022EF HuttonMaintainsBuy—
22 July 2022Cantor FitzgeraldInitiatesOverweight—
17 Mar 2022EF HuttonMaintainsBuy—
15 Mar 2022OppenheimerInitiatesOutperform—
30 Nov 2021B. Riley SecuritiesMaintainsBuy—
15 Jan 2021B. Riley FBRInitiatesBuy—
15 Jan 2021B. Riley SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIVI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BIVI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, BioVie, Inc. returned +2.7% against +17.5% for the S&P 500, dividends included.

BIVI vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26BIVIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BIVI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

BioVie, Inc. (BIVI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
−0.3×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−150.8%

Higher than 9% of US stocks

Return on assets
−79.1%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioVie, Inc. (BIVI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioVie, Inc. has a market value of $16.3M and an enterprise value of $5.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$22.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.0M.

  • Shares outstanding: 7.5M.

  • Trailing P/E: −0.2×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioVie, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BIVI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BIVIBioVie, Inc.$16.3M
26
AEONAEON Biopharma, Inc.$16.3M
51
ENLVEnlivex Ltd.$16.2M
40
PDSBPDS Biotechnology Corp.$16.1M
70
PASGPassage Bio, Inc.$16.1M
43
BCDABioCardia, Inc.$16.1M
42
NIKINiki Biosolutions, Inc.$16.6M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIVI news & analysis

BioVie advances Parkinson's Phase 3 development program with FDA engagement

Proactive Investors · 8 Sept 2026positive

BioVie announced it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease, has requested an End-of-Phase 2 meeting with the US FDA, and is working with Parkinson's disease clinical development experts to finalize the design of its Phase 3 trial.

Why it matters — This FDA engagement marks progress toward the next clinical stage for BioVie's lead Parkinson's candidate, a key milestone for the company's pipeline.

BioVie Announces Update to Parkinson's Phase 3 Development Program

GlobeNewsWire · 8 Sept 2026neutral

BioVie announced that it corresponded with the FDA in an End of Phase 2 Meeting to align on the Phase 3 trial design for the evaluation of bezisterim in early-stage Parkinson's disease, providing an update to its Parkinson's Phase 3 development program.

Why it matters — BIVI watchers would care because this update signals progress in aligning its Phase 3 trial design with the FDA for its Parkinson's candidate bezisterim.

BioVie completes final patient visit in Phase 2 Long COVID trial

Proactive Investors · 31 Aug 2026positive

BioVie Inc. announced completion of the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The company is a clinical-stage firm developing therapies for neurological and neurodegenerative diseases.

Why it matters — This milestone keeps the Phase 2 Long COVID trial on track toward a topline data readout, a key upcoming catalyst for BIVI watchers.

BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

GlobeNewsWire · 31 Aug 2026positive

BioVie announced completion of the last on-treatment visit in the treatment phase of its ADDRESS-LC Phase 2 trial evaluating bezisterim for neurological symptoms of Long COVID. This marks the conclusion of the trial's treatment phase for the clinical-stage company developing therapies for neurological and neurodegenerative diseases.

Why it matters — This milestone moves BioVie's ADDRESS-LC trial toward data readout, a key step for the company's bezisterim program in Long COVID.

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published a transcript of BioVie Inc. (BIVI) discussing the mechanism of action of bezisterim and the design of its SUNRISE-PD Phase II trial. The item covers the company's presentation on these topics rather than reporting new results.

Why it matters — BIVI watchers would care because the discussion provides detail on bezisterim's mechanism and the SUNRISE-PD Phase II trial design, which is central to the company's Parkinson's disease development program.

FAQ

Frequently asked questions about BIVI stock

What is the BIVI stock price forecast for 2026-2027?

The 2 Wall Street analysts covering BioVie, Inc. have a median 12-month price target of $5.26, with estimates ranging from $5 to $5.51. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIVI stock a buy right now?

Of the 2 analysts covering BioVie, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioVie, Inc. 26 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIVI?

As at 12 Sept 2026, BioVie, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will BIVI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +172.3% from the last close, and Ticker Nerd's factor model ranks BioVie, Inc. 26 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIVI stock forecast for 2030?

No analyst covering BioVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5.51 over the next 12 months.

How has BIVI stock performed over the past year?

BioVie, Inc. returned +2.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioVie, Inc. do?

BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurodegenerative disorders and advanced liver disease.

What is the latest news on BIVI?

The most recent item we track (Proactive Investors, 8 Sept 2026): "BioVie advances Parkinson's Phase 3 development program with FDA engagement". BioVie announced it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease, has requested an End-of-Phase 2 meeting with the US FDA, and is working with Parkinson's disease clinical development experts to finalize the design of its Phase 3 trial.

Company

About BioVie, Inc.

BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurodegenerative disorders and advanced liver disease. Its current pipeline centers on investigational drug candidates such as bezisterim, being studied for conditions including Alzheimer’s disease, Parkinson’s disease, and long COVID, and BIV201, which is being developed for complications related to liver cirrhosis and ascites. The company’s work is aimed at addressing chronic, debilitating illnesses through targeted pharmaceutical approaches that seek to reduce inflammation, support neurological function, and manage liver-related fluid retention. BioVie Inc. operates within the biotechnology sector and concentrates on diseases with significant unmet medical needs, making its programs relevant to both neuroscience and hepatology-focused drug development.

CEO Mr. Cuong Viet Do M.B.A. · 13 employees · United States · https://bioviepharma.com